8th Annual Sentinel Initiative Public Workshop


Public Workshop

8th Annual Sentinel Initiative Public Workshop

February 3, 2016 — 12:00AM–{12}:{00}{AM}

Renaissance Washington, DC Dupont Circle Hotel.

Contact Information

Adam Aten, MPH, MSc


Dr. Janet Woodcock, the Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration, provided the morning keynote address.


The Duke-Margolis Center for Health Policy hosted the 8th Annual Sentinel Initiative Public Workshop at the Renaissance Washington, DC Dupont Circle Hotel. This annual workshop serves as a forum to bring together leading experts and interested stakeholders to discuss the development of the Sentinel Initiative. With the passage of the Food and Drug Administration Amendments Act of 2007, Congress mandated that the U.S. Food and Drug Administration (FDA) develop a national electronic system to track the safety of regulated medical products. In response to this charge, FDA launched the Sentinel Initiative in 2008. Mini-Sentinel, a pilot project of the Sentinel Initiative, utilizes electronic health care data for postmarket risk identification and analysis of medical product safety. Since 2008, Mini-Sentinel has continued to develop with great interest from the stakeholder community and recently transitioned from pilot project to the full Sentinel System to help expand and enhance the FDA’s surveillance capabilities.

Specific topics that were addressed during the workshop include:

  • An overview of the current state of Sentinel safety surveillance activities;
  • Uses of Sentinel in medical product evaluations;
  • Development of current and future Sentinel tools and methods;
  • Sentinel’s role as a national resource for evidence generation; and
  • Stakeholder feedback on opportunities to enhance and modernize the Sentinel System.

Funding for this conference was made possible in part by a cooperative agreement from the Food and Drug Administration, Center for Drug Evaluation Research. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsements by the U.S. Government.

The workshop was captured on video and the segments displayed below are as follows:

Part 1: Welcome and Overview; Keynote Address; The Sentinel Initiative: Perspective from FDA’s Leadership; State of Sentinel Safety Surveillance Activities 

Part 2: Selected Sentinel Medical Product Evaluations; Current and Future Development of the Sentinel System

Part 3: Developing a National Resource for Evidence Generation

Part 4: Stakeholder Perspectives on Opportunities to Enhance and Modernize Postmarket Drug Safety Surveillance; Closing Remarks